SRTOY.US Sartorius Stedim Biotech S.A
- Market cap
- USD 23.8B
- P/E
- 62.8x
- P/B
- 4.97x
- ROE
- 8.4%
- Dividend yield
- 0.32%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is SRTOY.US undervalued?
Graham numberThe Graham number of Sartorius Stedim Biotech S.A cannot be estimated reliably (the estimate is too far from the market price).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Sartorius Stedim Biotech S.A fundamental analysis
No fundamental analysis for Sartorius Stedim Biotech S.A yet.
Sartorius Stedim Biotech S.A stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Sartorius Stedim Biotech S.A
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides flui…
Full company profileSartorius Stedim Biotech S.A financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Sartorius Stedim Biotech S.A annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 1.05B | 1.08B | 1.21B | 1.44B | 1.91B | 2.89B | 3.49B | 2.78B | 2.78B | 2.85B | 3.08B |
| Gross Profit | 527M | 555M | 630M | 748M | 1.00B | 1.55B | 1.82B | 1.23B | 1.21B | 1.29B | 1.41B |
| Operating Income | 226M | 222M | 300M | 332M | 472M | 683M | 1.08B | 485M | 371M | 527M | 611M |
| EBITDA | 271M | 280M | 360M | 395M | 569M | 812M | 1.33B | 756M | 671M | 833M | 935M |
| Net Income | 154M | 161M | 208M | 235M | 336M | 414M | 876M | 310M | 175M | 255M | 372M |
| EPS | 0.17 | 0.17 | 0.23 | 0.25 | 0.36 | 0.45 | 0.95 | 0.34 | 0.18 | 0.03 | 0.04 |
| Balance Sheet | |||||||||||
| Total Assets | 1.20B | 1.40B | 1.57B | 1.82B | 3.07B | 3.95B | 5.07B | 7.74B | 8.26B | 8.01B | 8.17B |
| Total Liabilities | 432M | 524M | 527M | 643M | 1.59B | 2.22B | 2.55B | 5.07B | 4.23B | 3.89B | 3.71B |
| Shareholders' Equity | 758M | 872M | 1.04B | 1.16B | 1.46B | 1.66B | 2.45B | 2.64B | 3.99B | 4.09B | 4.45B |
| Cash & Short-term Investments | 43.0M | 45.4M | 43.2M | 45.9M | 69.6M | 237M | 133M | 126M | 689M | 434M | 175M |
| Total Debt | 102M | 160M | 150M | 135M | 587M | 626M | 1.14B | 3.68B | 2.87B | 2.60B | 2.35B |
| Cash Flow | |||||||||||
| Operating Cash Flow | 157M | 175M | 227M | 310M | 417M | 696M | 612M | 746M | 815M | 517M | 528M |
| Capital Expenditure | 79.7M | 127M | 177M | 136M | 159M | 324M | 431M | 474M | 340M | 378M | 310M |
| Free Cash Flow | 76.9M | 47.9M | 50.7M | 174M | 258M | 696M | 182M | 273M | 475M | 140M | 218M |
| Ratios | |||||||||||
| ROE | 20.3% | 18.5% | 20.1% | 20.2% | 23.0% | 25.0% | 35.8% | 11.7% | 4.4% | 6.2% | 8.4% |
| ROA | 12.9% | 11.5% | 13.2% | 12.9% | 10.9% | 10.5% | 17.3% | 4.0% | 2.1% | 3.2% | 4.6% |
| Net Profit Margin | 14.6% | 14.9% | 17.2% | 16.3% | 17.6% | 14.4% | 25.1% | 11.2% | 6.3% | 9.0% | 12.1% |
| Debt to Equity | 0.13x | 0.18x | 0.14x | 0.12x | 0.40x | 0.38x | 0.46x | 1.40x | 0.72x | 0.64x | 0.53x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Sartorius Stedim Biotech S.A dividends
- Dividend yield
- 0.32%
- Forward dividend
- 0.08 USD
- Payout ratio
- 25.3%
- Ex-dividend date
- Apr 1, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | EUR 64.5M | 0.01 | 25.3% |
| 2024 | EUR 67.1M | 0.07 | 38.3% |
| 2023 | USD 133M | 0.14 | 42.8% |
| 2022 | EUR 116M | 0.13 | 13.3% |
| 2021 | EUR 62.7M | 0.07 | 15.1% |
| 2020 | EUR 31.3M | 0.03 | 9.3% |
| 2019 | EUR 52.5M | 0.06 | 22.4% |
| 2018 | EUR 42.4M | 0.05 | 20.4% |
| 2017 | EUR 38.7M | 0.04 | 24.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Sartorius Stedim Biotech S.A
- Insiders 0.00%
- Institutions 0.01%
- Public & others 100.00%
- Shares outstanding 973M
- Free float 278M
Sartorius Stedim Biotech S.A company profile
- Company name
- Sartorius Stedim Biotech S.A
- Ticker
- SRTOY.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 10,483
- Fiscal year end
- December
- Address
- Zone Industrielle Les Paluds, Aubagne, France, 13781
- Phone
- 33 4 42 84 56 00
- Website
- sartorius.com
About Sartorius Stedim Biotech S.A
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; reagents; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides fluid management services; biolayer interferometry instruments; microbiology testing, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; screening instruments; biomolecule analysis tools; batch liquid chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; water purification systems; and weighing products. In addition, the company offers data analytics software; process automation platform and software; and transfection reagents and plasmid DNA solutions. The company has a collaboration with Bio Usawa Biotechnology, Ltd. focusing on developing and manufacturing monoclonal antibodies in Sub-Saharan Africa to tackle oncology, diabetes-induced eye diseases, infectious diseases, and autoimmune conditions. It serves manufacturers of medications, vaccines, food, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. Sartorius Stedim Biotech S.A. is a subsidiary of Sartorius AG.
Sartorius Stedim Biotech S.A management
2- Dr. Rene FaberCEO & Director · born 1975
- Ms. Petra MullerHead of Investor Relations